Method of obtaining derivatives of pyrimido /4,5-d/quinoline or their optically active isomers or th

专利摘要:
Trans-(+/-)-2-Amino or substituted amino-4-permissibly-substituted 6-lower alkyl or allyl-5,5a,-6,7,8,9,9a,10-octahydropyrimido[4,5-g]quinolines, the corresponding trans-(-)-stereoisomers and salts thereof, useful in treating anxiety, Parkinson's Syndrome, sexual dysfunction, depression, hypertension and elevated prolactin levels, and intermediates useful for the synthesis thereof.
公开号:SU1364238A3
申请号:SU843784051
申请日:1984-08-21
公开日:1987-12-30
发明作者:Линн Николс Цинция；Карл Корнфельд Эдмунд；Мортенсен Формен Марк；Менерт Шаус Джон；Линн Хазер Дайана；Нолан Бухер Ричард；Тайвай Ванд Девид
申请人:Эли Лилли Энд Компани (Фирма)；
IPC主号:

专利说明:

eleven
This invention relates to a process for the preparation of pyrimido derivatives f4, 5-quinoline, or their optically active isomers, or their pharmaceutically acceptable acid addition salts, of new biologically active compounds that can be used in medicine.
The purpose of the invention is to obtain new derivatives in the pyrimido range; 4,5-dO-quinoline, which are active agonists and D-2 dopaminases, which do not cause any side effects, as well as have the ability to reduce blood pressure and affect the sexual behavior of male mammals (restore or remove arousal ).
Raw materials and intermediate products.
Example A. Preparation of 4aR, 8aE-1-p-propyl-6-oxodecahydroquinoli on.
A solution of 10 g of (-) - di-p-toluoyl-tartaric acid in 75 ml of preheated methanol is added to a solution of 5.05 g of dl-I-n-propyl-6-oxydehydroquinoline solution in 15 ml of methanol. The reaction mixture is heated to boiling and then cooled to ambient temperature. After incubation overnight at ambient temperature, crystallization is added by adding previously obtained seed crystals. The tartaric acid crystalline salt is separated by filtration, the precipitate is washed with methanol, and the yield is 2.813 g (.18.7%) of a white crystalline solid (-) - di-β-toluoyl tartrate 4aR, 8aR-1-n-nopro-1-6-oxodecahydroquinoline; fo j -107.49 ° (MeOH, with 1); Recrystallization of the salt from methanol yields 1.943 W1 / -108.29
g optically pure salt ° (MeOH, s 1).






The () -d-p-toluoyl tartrate salt thus obtained is treated with a dilute aqueous solution of sodium hydroxide 5 and the resulting basic solution is extracted with methylene dichloride. The methylene dichloride extract is dried, the solvent is concentrated 5 and the solvent is removed in vacuo. The resulting residue was distilled to give 4aR, 8aK-1-p-propyl-6-oxydecahydro quinoline as a colorless oil, C 0/3 2 -88.51 ° (MeOH, s. 1).
0
five
0
Other 1- (alkyl, allyl, benzyl, or cyan) -6-oxodecahydroquinolines can be cleaved in a similar manner.
Example B: Preparation of 4aS, 8aS-1 -rr-propyl-6-oxodecahydroquinoline.
The cleavage of trans (±) -1-p-propyl-6-oxo-decahydroquinoline was carried out in accordance with the following procedure. 10 g of (-) - di-p-toluoyl tartaric acid in a solution of 75 ml of thermal methanol is added to a solution containing 5.05 g of trans- (±) -1-p-propyl-6-oxodecahydroquinoline in 75 ml of methanol. The reaction mixture is brought to a boil, and then cooled to ambient temperature. After incubation overnight at ambient temperature, crystallization is caused by the addition of pre-prepared seed crystals. The crystalline salt of vin-, 5 hydrochloric acid is filtered off, the precipitate is washed with methanol, the yield is 2.813 g (18.7%) of a white solid crystalline substance containing (-) - di-p-toluoyl tartrate 4aK, 8aR-1-iS -propyl-6 -oxodecahydroquinoline, cil -107.49 ° (MeO H, s 1).
Filtrates and mother liquors containing tartrates are combined, and the combined solutions are treated with alkali, which are formed in this way.
B
the free bases are extracted into a water-immiscible solvent to obtain a solution of 1-nap 1-6-oxodecahydroquinoline enriched in the 4aS, 8a3 isomer and depleted in the 4aR, 8aK-isomer. In accordance with the aforementioned procedure, the solution was treated with (+) - ditoluoylvinic acid monohydrate to obtain 4aS, 8aS-1-n-n-propyl-6-oxo-dehydroisoquinoline- (+) - di-toluoyl tartrate, having about 80% of its optical purity (her - enantiomorphous excess). 20 g of salt were crystallized from 250 ml of methanol, which gave 12 g of a white crystalline powder, melting with decomposition at 167.5-169.5 ° Ci +106.3 (methanol, 1.0); (506.7 ° (methanol, 1.0). The optical purity is about 90% of it. The second collection, obtained from the mother liquors of the said crystallization, yields 2.3 g of a white solid, melting with
0
five
at 1 66-1 66, 5 ° С-, с / io. g / t25 schl o (eta 106.6
  + 5JO, 8 °
NOL, c 1.0 for both), determining optical purity of about 94% of it. Recrystallization of the first and second harvests from methanol gives a white solid from which the free base is obtained by standard procedures. The free base is distilled and 4.14 g of a colorless oil is obtained, melting at 82-86 ° C at a pressure of 0.13 Torr, including 4aS, 8aS-1-p-propyl-6-oxodecahydroquinoline; o / s + 86.2 °; “+376.6 (methanol, c 1.0 for both rotations); optical purity is about 98%.
Trans - (+) - 1-p-Propyl-6-oxodeca-hydroquinoline can be directly treated with (+) - di-p-toluoyl-tartaric acid to obtain 4aS, BaS-1-p-propyl-6-oxo-decahydroquinoline- - (+) - di-p-toluoyl tartrate, which is purified by the procedures outlined above.
Example Preparation of trans - (+) - 1-p-propyl-b-oxo-7-ethoxycarbonyldecahydroquinoline.
A suspension of 790 mg of sodium hydride (55% in mineral oil) is placed in a 50 ml round bottom flask, the mineral oil is removed by three washes with hexane. The solid residue of sodium hydride is suspended in 8 mp THF (tetrahydrofuran) and 1.45 ml (1.41 g) added together with one drop of anhydrous ethanol. The resulting solution is heated to boiling point using a reflux condenser and 1.1 g of trans- - (+) - 1-P-propyl-6-oxodecahydroquinoline in 5 ml of THF are added over 5 minutes. The resulting mixture is heated to boiling point using a reflux condenser overnight. Using TLC, it was established that no starting materials were present in the mixture. The reaction mixture is placed in water, while the pH of the aqueous layer reaches 14, the alkaline layer is extracted with methylene dichloride. The pH of the aqueous layer is adjusted to 9 and the alkaline layer is extracted again with methylene dichloride. The methylene dichloride extracts are combined, dried, the solvent is removed, 1.56 g of trans- (t) -1 -1 p-propyl-6-oxo-7-ethoxycarbonyldecahydroquinoline is obtained in the form of an oil. To chromatograph the residue over silica gel
0
five
0
o
Woelm (1pO-200 mesh) used as eluent a mixture of solvents ether - hexane in a 1: 1 ratio, containing traces of a 14 N aqueous solution of ammonium hydroxide. The fractions containing the desired product are combined and 880 mg (55% yield) of a yellow oil are obtained. The NMR method has shown that ketoester exists in an enol form.
EXAMPLE D: Preparation of trans - (+) - 1-G7-propyl-6-oxo-7-dimethylaminomethylene decahydroquinoline. 4 g of trans - (+) - 1-p-propyl-6-oxo5 decahydroquinoline is added to a solution containing 5.6 g of potassium t-butoxide in 50 ml of anhydrous, double distilled tetrahydrofuran. The reaction mixture is stirred under nitrogen for 30 minutes. Then 3.6 ml of ethyl formate is added dropwise, cooling the reaction mixture in a bath containing ice-alcohol. After the addition is complete, the reaction mixture is stirred under nitrogen at ambient temperature overnight. The pasty reaction mixture is neutralized with glacial acetic acid. After adding methanol to the paste, 1 ml of dimethylamine and molecular sieves are added to it. Then the reaction mixture was stirred for 48 hours under nitrogen atmosphere, filtered. The filtrate is evaporated to dryness in vacuo. To the residue is added
With water, the aqueous mixture is extracted three times with equal volumes of methylene dichloride. The methylene dichloride extracts are combined, washed with water, and dried. Evaporation of methylene dichloride gives 15 g (81.4%) of trans - (+) - p-1-p-propyl-6-oxo-7-dimethylaminomethyl-decahydroquinoline.
PRI me R E. Preparation of TRANS- (±) -2-amine-6-cyan-5,5a, 6,7,8,
5 9.9a, 10-octahydropyrimido (4,5-) quinoline.
The reaction mixture is prepared from 16 g of trans- (t) -1-metsh1-6-oxo-decahydroquinoline, 26 g of cyan bromide and
Q 450 ml of methylene dichloride, stirred overnight at room temperature, and then extracted three times with 1 N aq.-11m hydrochloric acid solution. The acidic extract is washed with a saturated sodium bicarbonate aqueous solution and then dried. The volatiles were removed in vacuo. The resulting residue was 18.8 g. Trans- (±) -1-cyano-6-oxodecahydroquino
lina in the form of semi-solid oil. Chromatography of this oil over Florisil silica gel using chloroform as eluent yielded pure material fractions, weighing 11.5 g together, yield 66%. The oil crystallized on standing and forms white crystals.
The reaction mixture of 4.18 g of trans- (±) -1-cyano-6-oxodecahydrochicoline, 5.0 g of tris-dimethylaminomethane and 50 ml of toluene is heated to boiling using a reflux condenser under nitrogen for 5 hours and then concentrated in a vacuum. 5.67 gels of a purified yellow solid, trans - (+) - 1-cyan-6-oxo-7-dimethylaminomethylenene decahydroquinoline, are obtained. This crude product is mixed with 2.25 g of guanidine carbonate in 100 ml of anhydrous methanol. The reaction mixture is heated to boiling point using a reflux condenser in a nitrogen atmosphere for no-25 hydropyrimido (4,5-Q) quinoline. It can then, and then concentrated in vacuo. to be alkylated by a lower alkyl halide
15
20
waste is extracted three times with a mixture of chloroform-isopropanol solvent in a ratio of 3: 1 by volume. The organic extracts are combined, dried. Removal of the solvent in vacuo gives 0.43 g of a light yellow powder of trans- (±) -amine-5.5a, 6.7, 8.9.9a, 10-octahydro-pyrimido (4, 5- j.) Quinol- new free base. The free base is converted to the hydrochloride salt, which is recrystallized from a solvent mixture of methanol - acetate, to obtain a crystalline material having a mp. about .
Analysis (after drying at 150 ° C):
Calculated: C 47, 66; H 6, 55, - N 20,21. ,
Found: C 47.37; H 6.65; N19.91.
The thus prepared trans (±) -2-amine-5.5a, 6.7, 8.9, 9a, 10-octane solid residue is triturated with hot methanol and filtered. The sludge is pressed twice with methanol and once with ether. 4.11 g (78%) of trans- (±) -2-amine-6-cyano-5.5a, 6.7, 8.9.9a, 10-octahydropyrimido (4, 5-) -quinoline are obtained, having the following physical characteristics: mass spectrum, molecules it is 229; IR spectrum peaks (cm): 3307.18, 3157.70, 2202.87, 1660.83, 1564.38, 1486.26.
Calculated: C, 62.86; H 6.59, - N 30.54.
Found: C, 63.18; H 6.70; N30.24.
PRI me R F. Preparation of trans - (+) - 2-amine-5,5a, 6,7,8,9,9a, 10-octahydropyrimido (4,5 - §.) Quinoline. The reaction mixture of 1.66 g of the 6-cyano compounds of Example E, 9.7 g of zinc powder, 200 ml of acetic acid and 50 ml of water is heated to boiling using a reflux condenser under nitrogen atmosphere for 24 hours and then stirred for 48 hours at room temperature. The volatile material is removed from the reaction mixture in vacuo, and the resulting dissolved in water. The aqueous solution is acidified with a 50% aqueous solution of sodium hydroxide (final pH value in the range of 10-11) .. The injected precipitate is filtered, fil0
5 hydropyrimido (4,5-Q) quinoline. Can be alkylated by lower alkyl halide
five
0
waste is extracted three times with a mixture of chloroform-isopropanol solvent in a ratio of 3: 1 by volume. The organic extracts are combined, dried. Removal of the solvent in vacuo gives 0.43 g of a light yellow powder of trans- (±) -amine-5.5a, 6.7, 8.9.9a, 10-octahydro-pyrimido (4, 5- j.) Quinol- new free base. The free base is converted to the hydrochloride salt, which is recrystallized from a solvent mixture of methanol - acetate, to obtain a crystalline material having a mp. about .
Analysis (after drying with an overnight temperature of 150 ° C):
Calculated: C 47, 66; H 6, 55, - N 20,21. ,
Found: C 47.37; H 6.65; N19.91.
Thus prepared trans- - (±) -2-amine-5.5a, 6.7, 8.9a, 10-octa0
five
0
five
0
five
or allylated with allyl halide to form the proposed compounds.
Some of the above mentioned preparations were carried out with the racemate. The same chemical steps can be carried out on separated trans - (-) - or trans - (+) - stereoisomers to obtain optically active intermediates and final products.
Example Preparation of trans- - (+) - 2-amine-4-hydroxy-6-p-propyl-5,5a, 6,7,8,9,9a, 10-octahydropyrimido (4,5- -) quinoline.
A reaction mixture of 2.0 g of trans- (+ 3-1-p-propyl-6-oxo-7-ethoxycarbonyl decahydroquinoline (prepared in example C), 20 ml of anhydrous ethanol, and 0.67 g of guanidine carbonate are heated to boiling point using a reverse fridge under nitrogen overnight. Obra, t
The precipitated white precipitate is filtered, drained and washed with ethanol, dried, yield 1.36 g. The precipitate is squeezed out and dissolved in 52 ml of O, 1 aqueous hydrochloric acid solution. The acidic mixture is filtered and the filtrate is concentrated in vacuo. The solid residue is dissolved in boiling methanol. The methanolic solution is filtered and the hydrochloride is thus prepared trans - (+) - 2-amine-4-hydroxy-6-p-propyl-5,5a, 6,7,8,9,9a, 10-octahydropyrimyl713642388
to (4,5-g) quinoline crystallizes, the trans- (±) -2-amine-6 salt of mead is used to grind 0.79 g of product. Svobodotil-5,5a, 6,7,8,9,9a, 10-octahydro-pyribasic had the following physically hemo (4,5-) quinoline, re-crystalline characteristics: mass spectrum, molecules from ethanol. Get 66 ml
a polar ion 262. dihydrochloride salt having so pl.
Calculated: C 64.09 H 8.45; 262-275 ° C (with decomposition) and the following
N 21.36. Analysis (after drying at a temp. Found: C 64.18; H 8, 51; N 21, 1. 3.ture 150 s):
The hydrochloride salt had the following IQ. Calculated: C 49.49i H 6.92;
physical characteristics: mass-N 19,24.
spectrum, molecular ion 262. Found: C 49.61; H 7.03; N 18.92.
Finite products. High temp: drying drying was not an example. 1. Preparation of trans-obzhoma, as it was found that
- (+) 2-amine-6-methyl-5,5a, 6,7,8,9,9a, -15after drying at lower temperatures 10-octahydropyrimido (4.5-5) quinoline. This hydrochloride salt is crystal-reaction mixture of 1.8 g, it is trans-talized in the form of a solvate, and for (±) -1-methyl-6-oxodecahehydroquinoline for the reproducibility of the dissolution analysis, and 2.2.2 g of tris-dimethylamine methane must be removed. 18 ml of toluene are heated to. 2 ° C. Preparation of a boil trans using reverse - (+) - 2-amine-6-p-propyl-5,5a, 6,7,8, - refrigerator for 12 hours at atm-9.9a, 10-octahydro-pyrimido (4,5-) hydroxyl of nitrogen. Additionally add a leg.
0.8 g of tris-dimethylamine methane and kip - The reaction of example 1 was repeated, t in a nitrogen atmosphere using 25 except that 1 trans- (±.) - an additional 1-l-propyl-6-oxo- reflux condenser 7-dimethylamine-methy- for 5 hours. Then, the reactive Decachydroquinoline was reacted and the mixture was concentrated in vacuo to dryness with 0.4 g of guanidine carbonate in 20 ml. The resulting residue containing anhydrous ethanol, (trans - (+) trans - (+) - 1-methyl-6 -oxo-7- (dimethyl- OQ-propyl-6-oxo-7-dimethylaminomethylamine-methylene) -decahydroquinolin, rast-decahydroquinolin bstr entrained from thieves in 40 ml of ethanol, to which 1.5 g of guanidinecarbonate.quinoline and tris-dimethylaminemethane are added to the transfer of (+) - 1-p-propyl-6-oxodecahydro - and the resulting mixture is heated with a-according to the above procedure - by changing the reverse refrigerator in te). The reaction mixture is boiled overnight at reflux temperature under a no-nitrogen atmosphere. After cooling until crystallization begins, the crystalline precipitate is cooled in an ice bath and light yellow is filtered, drained, washed with ethanol containing crystalline precipitate, yield 0.68 g (38%) light trans - (+) - 2 -amin-6-p-propyl-3,5a, 6, - yellow powder. This material was 7, 8, 9, 9a, 10-octahydropyrimido (4,5-) - dissolved in a 1 N aqueous solution of hydrochloroquinoline formed in the indicated perai acid. The acidic solution is then collected. The pressed precipitate was transferred to the core with 10% washed with ethanol and dried. The point of a smooth aqueous solution of natrium hydroxide is about 260 ° C. The yield is 0.6 g (61%). ri. The trans free base is (+) - Calculated: C 68.26; H 9.00; -2-amine-6-methyl-5,5a, 6,7,8,9,9a, 10-N 22,74.
octapirimido (4,5th) quinoline, nera Found: C 68.45; H8.87, - N 22.26. soluble in the alkaline layer, it was separated (trans) (±) -2-Amin-6-p-propyl-5,5a, leno and extracted with chloroform.6,7,8,9,9a, 10-octahydropiramide (4, The 5-chlorophorm extract is dried and the chloro-) quinoline is dissolved in 1 N aqueous form and stripped off in vacuo. The residue, hydrochloric acid co-solution and acidic trans-(1) -2-amine-6-methyl solution are extracted with ether. Then -5.5a, 6.7, 8, 9.9a, 10-octahydropyrimry acid solution is converted into basic (4.5-§) quinoline, suspended in this with 10% aqueous solution of zero, and ethanol solution nash; aytedkogo soda. The precipitated transgase-like hydrogen chloride .- (+) - 2-amine-6-p-propyl-5.5a, 6.7.8, - The solvent is distilled off in vacuo, a9.9a, 10-octo-pyrimido (4.5 - | J) the x- residue, the dihydrochlo-noline is filtered off. Free os.
913
The solution is dissolved in 1 N solution of hydrochloric acid. The species is removed in vacuo. The residue is recrystallized from hot ethanol. Yield 0.54 g (40%), prepared in this way trans- (t) -2-amine-6-n-propyl-5,5a5b dihydrochloride, 7.8,9,98,10-octahydro-pyrimido (4,5-) quinoline has so pl. 225-270 ° С
Calculated: C 49.74; H 7.75; N 16.57; C1 20.97.
 2HC - HjO
Found: C, 49.88; H 8.03; N 16.81; C1 20.87. :
After drying, the analysis showed that hydrated water and 0.5 mol of hydrogen chloride were lost, which gave one-half salt of trans - (+) - 2-amine-6-p-propyl hydrochloride 5,5a, 6, - 7 S 8.9 J 9a 510-octahydropyrimido (4,5-o) -quinoline.
Calculated; C 55.86; H 7.87 N 18.61; C1 17.03.
C, 4 B5HC1
Found: C, 55.49; H 7 / 83-, N 18.35 C1 17.03.
And e rime 3. The preparation of 5aR, 9aK 2-amine-6 -yg-propyl-5,5a, 6, 7,8,9, - 9a, 10-octahydropyrimido (4,5-Q) quinoline .
Following the procedure of Example 1, 4aR, 9aR 1-p-propyl-6-oxo-7-dimethylamine-methylene decahydroquinoline (prepared from 4aR, 9aR-1-p-propyl-6-oxydidecahydroquinoline and tris-dimethylamine-methane, as shown in example A), it is reacted with guanidyl carbonate in an anhydrous ethanol solution. The reaction mixture is worked up as in Example 1, 2.4 g of 5aR is obtained; 9aR-2-amine-6-p-propyl-5,5a, 6,7,8,9, - 9a, 10-octahydropirimnd (4,5-) quinoline.
The product is suspended in ethanol and hydrogen chloride gas is bubbled through the suspension. The resulting solution is evaporated to dryness in vacuo, and the residual yellow oil is dissolved in 10 ml of ethanol. Ether is added at the point of beginning sedimentation and the mixture is heated on a steam bath. After cooling, the formed fine powdery crystals are filtered. The pressed precipitate is washed with ethanol to give 0.72 g of the 5aR dihydrochloride salt, 9aR-2-amine-6- -n-pr opil-5S, 5a, 6.7 5 8.9, 9a, 10-octahydropyrimido (4 , 5-) quinoline.

ten
Analysis (after drying at temp. 180 ° C).
Calculated: 17.55.
Found: C, 52.81; H 7.75;
Molecular ion 246,
Optical rotation fo JrL -99,6 °;
111--374.8C 52.67; H 7.58;
N 17.65.
"9
PRI me R 4. Preparation of trans- (±) -2-dimethylamine-6-p-propyl-5,5a, - 6,7,8,9,9a e10-octahydropyrimidr (4,5-) quinoline.
The reaction mixture is prepared from 4.7 g of trans - (+) - 1-p-prop 1-6-oxo-7-dimethylamine methylene decahydroquinoline and 2.5 g of N, N-dimethylglyanidine hydrochloride in 50 ml of anhydrous ethanol, heated under an atmosphere of nitrogen overnight, then cooled and volatile constituents removed in vacuo. The residue is dissolved in ztilacetate and the ethyl acetate solution is treated with an excess of 10% aqueous sodium hydroxide solution. The resulting trans- (t) -2-dimetslamin-6-n-propyl-5,5a, - 6,7,8,9,9a, 10-octahydropyrimido (4,5 - () quinoline, insoluble in the base layer, remains in the ethyl acetate layer. The aqueous layer is separated, and the ethyl acetate layer is extracted once with water and once with a saturated aqueous solution of sodium. The ethyl acetate layer
dried, and ethyl acetate removed in vacuo. 0.75 g of orange oil is obtained. The oily residue is chromatographed over Florisil silica gel using hexane containing increasing amounts (1-50% by volume) of ethyl acetate as eluent. Fractions that showed when they contain trans - () - 2-dimethylamine-6-n-propyl-5,5a, 6,7,8, - 9,9a, 10-octahydropyrimido (4,5-a) xi - nolin, are combined and the solvent is removed from the combined fractions in vacuo. The resulting residue is dissolved in ethanol and hydrogen chloride gas is passed through the solution to obtain the corresponding dihydrochloride salt. Ethanol is removed from the solution in vacuo, and the dihydrochloride salt is crystallized from methanol-ethyl acetate-solvent mixture to obtain 0.170 g of a white solid having a molecular ion of 274, and so on. about .
Calculated: C 55.33; H 8.13; N 16.13.
 1364238. 12
Found: C 55.67j H 8.19 N 16.19. The chloride extracts are combined and the volume of the p and m I p 5. Preparation. The combined extracts are dried, rastrans- (+) - 2-methylamine-6-p-propyl- the wither is evaporated, get 2.7 g
-5,5а, 6,7,8,9,9a, 10-octahydropyrim-trans - (+) - 1- -propyl-6-oxo-7-adylethyl (4,5-) quinoline. decahydroquinoline, Crude protrans- (±) -2-Methylamine-6-p-propduct of the reaction (without further purification) drank-5.5a, 6.7.8.9.9a, 10-octahydropi-mixed with 0.9 g guanidine carbonate, rimido (4,5-) quinoline is prepared, 40 ml of ethanol are added to the mixture following the procedure of Example 4, but replacing N, they are heated under a nitrogen atmosphere with N-methylguanidine by refluxing up to product is purified by chromatography on boiling points. Then, the reaction gel of Florisil, using as a mixture, is evaporated to dryness and with a crude eluent of methylene dichloride, the contents of the product are chromatographed over silica gel with increasing amounts, Florisil gel. Fractions showing - (0-10%) methanol; yield 0.66 g. The detergents that they contain trans- (1) -2-hydrochloride salt are prepared by adding - amine-4-methyl-6-p-propyl-5,5a, 6,7,8, the equivalent amount of 9.9 a, 10-octahydropyrimido (4.5–9) x – 0.1 N hydrochloric acid to a solid velloline formed in the above substance and recrystallization of the product – action is combined, and 270 mg is obtained. from methanol, yield 599 mg. M.p. of the free base to which it is up to about 240 ° C., 10 ml of a 0.1 N aqueous solution
Calculated: C 60.69 H, 8.49; hydrochloric acid. Obtained by such obN 18,87; Cl 11.94 times the dihydrochloride salt is recrypted. Found: C 60.96 N 8.53; N 19.07; 25 are tallyed from ethanol, m.p. about
C1 11.74.240 ° C, mass spectra: molecular ion
In examples 1, 2, 4 and 5 optically, 260, a small peak of 268.
active 5aR, 9aR- or 5aS, 9aS-npo-Calculated: C 54.05 H 7.86;
Derivatives can be prepared N 16.81.
from the desired 4aR, 8aR- or 4aS, 8aS- Found: C 53.93; H 7.98; N 16.61.
, -alkyl-6-oxo-7-dimethylamine-Methyl Prime 7. Preparation of translendecahydroquinoline and a suitable - (+) - 2-amine-4-chloro-6-p-propyl-5,5a, guanidine .6,7, 8.9, 9a, 10-octahydropyrimido (4.5P and m 6). Preparation of trans-1) quinoline.
- (+) - 2-amine-4-methyl-6- -propyl-5,5a, -4-hydroxy product obtained at 6, 7.8, 9.9 a, 10-octahydropyrimido (4.5-35 heated with using an ob-quinoline, portable refrigerator to a temperature
13, 7 ml of 1.6 M p-butyl boil with 4 ml of phosphorus oxychloride are added. Implement in hexane to a solution, containing a mixture containing the resulting 3.1 ml of diisopropylamine and 22 ml in the indicated reaction trans - (+) - 2- THF, at a temperature of about 0 ° C in at-amine- 4-chloro-6-p-propyl-5,5a, 6,7,8, - to the nitrogen sphere, the reaction mixture pe-9,9a, 10-octahydropyrimido (4,) is stirred for 30 minutes. Subsequently, the lignin is placed on ice and 2.0 g of trans - (+) - 1-p-aqueous aqueous mixture is added to it, alkalinized. 0c-β-propyl-6-oxodecahehydroquinoline is filtered into a non-new mixture and an insoluble large amount of THF, the supported material (30 mg) is dissolved in this mixture with a 0.1 N aqueous solution of hydrochloric acid about - 78 C. The solution is stirred. The thus prepared hydro- 2 h during which time the chloride salt was recrystallized with 1.1 ml of acetyl chloride and continued to flow from ethanol gave 13.6 mg transmixing for 30 minutes at - - (+) - 2 -amine-4-chloro-6-p-prop 1-5.5a, - and then at room temperature-6,7,8,9,9a, 10-octahydro-pyrimido (4,5-type 2 h. After this, the reaction- 5) quinoline hydrochloride having a mixture is placed in water and forming the following physical characteristics: as a result, the aqueous mixture of mass spectra, molecular ion 280, is acidified to pH 9-10 with 1 N aqueous solution Peak 282. Hydrochloric acid ore. Water growth-Calculated: C 53.00; H 6.99; the thief is extracted three times with equal N 17.66. volumes of methylene dichloride. Methylendeen-Found: C 53,15; H 6.92; N 17.77.
The 4-bromo derivative can be prepared similarly to the substitution of POCl. on RVg in the above reaction.
PRI me R 8. Preparation of trans- (t) -2-acetylamine-6-p-propyl-5,5a, 6, - 7 5 8,9,9a, 10-octahydropyrimido (4,5 -) - quinoline ..
To a solution containing 0.75 g of trans - (+) 2-amine-6-p-propyl-5,5aj 6, - 7 j8,9,9as, 10-octahydropyrimido (4.5-9) - quinoline 20 ml of pyridine, 0.34 g of acetic anhydride is added dropwise. The reaction mixture is heated under a bed of nitrogen to the boiling point d by using a reflux condenser overnight. Thin-layer chromatography at this point determined that the starting material was still present, therefore about 1.5 ml of acetic anhydride was added and the reaction mixture was again heated in a stream of nitrogen to a boiling point using a reflux condenser ( 9si by volume) in a dissolving system containing ammonia j, it was determined that the reaction was largely completed, but that
some raw material is still present. The reaction mixture is concentrated in vacuo, and the resulting residue is triturated in hot ethyl acetate. After cooling the crystals formed, it is filtered5 to obtain 340 mg of trans- (±) -2-acetal-amin-6-p-propyl-5j5a56, 7.859.9a, 10-octahydropyrimido () quinilin.
Rf 0.7; molecular ion 288; NMR and IR spectra in accordance with the proposed structure,
PRI me R 9. Preparation of trans - (+) - 2 benzoylamine 6-p-propyl-5,5a, - 65758s959a, 10-octahydropyrimido (4,5- - |) quinoline.
Following the procedure of Example 8, trans - (4 -) - 2-amine-6-p-propyl-5.5a, 6.7 j8.9, 9as10-octahydropyrimido (4,5-) quinoline is reacted with benzoyl chloride in pyridine solution The 450 mg residue of a yellow-orange oil obtained after treatment of the reaction mixture is chromatographed over Florisil silica gel using chloroform with increasing amounts (0% W%) of methanol as eluent. Fraction 10 containing 2 - benzoylamine compound
They are evaporated in vacuo, the residue is dissolved in ethanol and hydrogen chloride gas is passed through the solution. The addition of ether at the point of the beginning sedimentation of the precipitate gives trans- (±) -2-benzoylamine-6-p-propyl-5.5a dihydrochloride, 6.7.8.9.9a, 10-octagidropyrimido (4.5- ) quinoline, molecular ion 350,
Analysis (after drying at 130 ° C):
Calculated from 59.57; H 6.67; N 13.23.
Found: C, 59.35; H 6.85j N 12.99,
Example 10. Preparation of 5aS, 9a8-2-amine-6-p-propyl-5.5a, 6,7,8,9, - 9a, 10-octahydropyrimido (4,5-j) quinoline. .
five
0
five
To a solution of 3.37 g of 4aS, 8aS- -1-n-pr-spil-6-oxodecahydroquinoline (prepared in Example B), in 60 ml of toluene and cod were added 6.60 g of tris (dimethylamine) methane. The resulting mixture is heated for 4 hours to boiling point using a refluxing cooler, after which it is determined by TLC by the absence of a spot corresponding to the starting material. The concentration of the reaction mixture gives 4.813 g of a yellow oil, which is chromatographed on a column of 50 mm x X 30 cm over silica gel using 8% methanol in methylene dichloride with concentrated ammonium hydroxide as eluent. The fractions in which the content of 4aS, 8aS-1-n- -propyl-6-oxo-7-dimethylaminomethylene-decahydroquinoline is determined by TLC is obtained to obtain 3.651 g of a yellow oil. This material is dissolved in 30 ml of ethanol without further purification, and the solution
 2.56 g of guanium and dinocarbonate in 70 ml of anhydrous ethanol are added to the suspension. The reaction mixture is heated to reflux for 18 hours using a reflux condenser, and then cooled in an ice bath. The precipitate which forms in this way is filtered off to obtain 3,506 g of fine light yellow yellow needles containing salt 5aS, 9a8-2-amine-6-p5 -propyl-5,5a, 6,7,8,9,9a, 10-octahydro-pyrimro-co (4.5–9) quinoline, The salt thus obtained is converted into the hydrochloride salt by the standard procedure.
0
salt. The dihydrochloride salt is dissolved in water. The formed acidic water is converted into basic using sodium hydroxide. The free base, insoluble in the alkaline layer, is separated and extracted into methylene dichloride. By evaporation of the extract to dryness, a white foam is obtained, which is dissolved in solvent mixtures methanol methylene dichloride in a 1: 1 ratio and the solution is saturated with gaseous HC1. By concentrating the solution, a yellow foam is obtained, which is recrystallized from methanol-ethyl acetate; a white powder is obtained containing the 5aS dihydrochloride salt, 9a8-2-amine-6-p-propyl-5.5a 6.7.8, 9.9a, 10- Octahydropyrimido (4,5- -) quinoline, having the following elemental analysis:
Calculated: C 52.67; H 7.58; N 17.55; C1 22.21.
Found: C 52.39; H 7.36; N 17.31 C1 22.40.
o (25 +108, o (/ +405.2 (both in methanol, c 1.0).
Biological tests of the pyrimido G4.5- / y quinoline derivatives obtained by the described method were carried out.
Adult male Sprague-Dawleg rats weighing about 200 g are placed in an air conditioned room with adjustable lighting (lighting from 6 am to 8 pm), giving laboratory food and water ad libitum. Each rat, 18 hours before the administration of the investigational medicinal product, received an intraperitoneal injection of 2.0 mg of reserpine in an aqueous suspension. Reserpine was administered to keep prolactin levels in rats permanently elevated. The test compound was dissolved in 10% ethanol and injected intraperitoneally at doses of 100 to 1 mg / kg. Each dose of the test compound was applied to a group of 10 rats, and a control group of 10 males received an equivalent amount of 10%. ethanol. One hour after the treatment, all the rats were decapitated, and the Sshor Otki samples (150 ml) were aliquoted for prolactin.
The difference between the level of prolactin in the treated and control rats divided by the level of prolactin in the control rats is equal to the percent inhibition of release of prolactin from
five
0
five
0
five
0
five
0
five
carried to a given dose. The data is given in Table. 1 and 2.
In some cases, each dose has been studied more than once, then the table shows the average values.
The proposed compounds are also active when applied through the esophagus, trans - (+) - 2-Amino-6-p-propyl-5,5a, 6,7,8,9,9a, 10-octahydropyrimido (4,5-) quinoline hydrochloride (the second compound in Table 1) at a dose of 10 mg when applied through the esophagus gave 74% inhibition, and at 50 mg / kg, 91% of inhibition was obtained.
The proposed dopamine-B-2 agonist compounds have been found to be effective in altering the behavior of rats affected by 6-oxopamine when testing compounds useful in the treatment of parkinsonism. In this case, put the experience on the affected rats with newly formed black stripes. A compound having a dopamine-agonist activity causes the rats to change contralateral cycles towards lesion. After a latent period of various compounds, the number of changes is calculated within 15 minutes.
The results of such a test are given in table. 3
The proposed compounds are also active when taken through the esophagus, despite the fact that fairly high doses are required to obtain a significant effect.
Compounds of the invention invented for lowering blood pressure in rats having spontaneous hypertension, as shown by the following experiment.
Adult male rats with spontaneous hypertension (CHS), weighing approximately 300 g, were anesthetized with sodium pentobarbital (60 mg / kg). The trache was cannulated, and the rats gave room air. Arterial blood pressure pulsation was measured from a cannled carotid artery using a STATHEM transducer (P23 ID). The arterial blood pressure value was calculated as diastolic blood pressure plus 1/3 pulse pressure. The heart rate was monitored with a cardio-tachometer. The drug solution was injected intravenously over 171364238
rez catheter inserted into the femoral

vein. Arterial blood pressure and heart rate were recorded on a multichannel oscilloscope (Vesmap, Model P511A). The study was performed 50 minutes after the intervention.
In tab. 4 shows the test results for trans- (±) -2-amine-6-p-propyl-5.5a, 6,7,8,9,9a, 10-octahydro-pyrimido (.4,5 g) quinoline . The change was measured immediately after the injection. The main boundary value
Frequency of introduction assumptions (PED)
to achieve eculation The total number of tanks with the assumption of the introduction required to achieve eculation
Each male rat was given a rat thief containing either a pure vehicle (1 millimolar acetic acid plus 1 millimolar acetic acid PLUS 1 millimolar ascorbic acid
acid) in water, or trans - {-) - 2- arterial blood pressure was g -amin-6-p-propyl-5,5a, 6,7,8,9,9a, 10-. 181 ± 1, 0 mm Hg, and the values of the hour-octagidropyrimido (4,5-) quinolingidottosis of heartbeats 366 +. rochloride in the amount of 25 mg / kg including ± 15 beats / min. of the carrier, subcutaneous injection for
trans () - 2-amine-6-p-propyl-5.5a, - 30 minutes before the study of behavior. Che 6,7,8,9,9a, 10-octahydropyrimido (4,5-Q Res week a week after testing the drug-d) quinoline and its trans (-) - stereoisomer are potent activators of cholinergic neurons in
. rat striatum, which leads to an increase in acetylcholine concentrations in the striatum.
Once again, the clean media was tested again.
The results of the experiment on 9 rats are given in Table. 5. A repetition of 25 tests at 0.25 µg was carried out with the following results (Table 6.
The ability of trans - (+) - or trans meanings are represented by x ± S.O. for - (-) - 2-amine-4-tolerated-6-11 rats). According to the data, -alkyl (or all-1) -octahydropyrimido. are given in table. 5, the drug (4,5-d) quinoline or its salt influenced by a drug causing a statistically significant effect on the sexual behavior of male mammals is illustrated by the following experiment.
Male rats used
40
It took at least 5 minutes for elution. Behavioral studies began with the placement of a sexually susceptible female rat in an area to study the behavior and immediately discontinued after the first cage followed by eculation. The following behavioral indicators were obtained:
The hidden period of the cage (ATP) or females to
first load
The latent period of tolerance from the injection room (SPDV) nor the female until the admission of the introduction of 50 (the latent period of ek - Time Interval SSPE)
Poste Cooling Interval (PEI)
Cage Frequency (ES)
The improvements in XPS and ES compared with treatment with the carrier, as well as with SPDV in comparison with the previous treatment with the carrier. These data show an improvement in sexual activity. In accordance with the data presented in table. 6, a single subcutaneous dose of the drug of 250 ng / kg caused statistically significant improvements in EIT compared with the previous treatment with the carrier. Despite the fact that there were no statistically significant differences in comparing the mean values of de time from room between drug and subsequent carrier responses, it is important to note that 6 out of 11 rats showed the best performance in each indicator of activity after treatment. drug compared to post-treatment with a vehicle, and 9 and 8 of 11 rats showed improvements in PC and PD, respectively. These data confirm that trans - (-) - 2-amine-6-l-propyl-5.5a dihydrochloride, 6,7,8,9,9a, 10-octa-hydropyrimido (4,5-d) quinoline influences behavior in doses up to 250 ng / kg. Similar experiments were carried out.
neither from the admission of the introduction to the eculation
The time interval is 55 from the eculation to the next charge. The total number of charges required;
18
Frequency of introduction assumptions
to achieve eculation The total number of tanks with the assumption of the introduction required to achieve eculation
Each male rat was given a solution containing either a pure vehicle (1 millimolar acetic acid plus 1 millimolar acetic acid PLUS 1 millimolar ascorbic acid).
Res week after drug testing
Once again, the clean media was tested again.
The results of the experiment on 9 rats are given in Table. 5. A repetition of the test at 0.25 µg was carried out with the following results (Table 6.
ten
20
25
nineteen
At the dose of the drug, 5 ng / kg sc, but no effect on the treatment was noted.
The effect of trans - (-) - 2-amine-6-p-pro Sh1-5.5a, 6,7,8,9,9a, 10-octahydropyimido (4,5-h) quinoline hydrochloride on sexual behavior male rats were also evaluated for those rats that did not have the ability to mate or the ability to achieve ejaculation for 30 minutes. The effect of 25 µg / kg of the subcutaneously administered drug on the sexual activity of impotent rats is presented in Table. 7. It turned out that the drug stimulates sexual behavior in those animals that had not previously manifested sexual behavior, and also enhances sexual behavior in those animals that were unable to achieve ejection. These animals showed significant recovery in emergencies after drug treatment.
In tab. 8 shows the activity of males reaching eculation.
The effect of trans- (±) and trans- (-) - 2- -amino-6-p-propyl-5,5a, 6,7,8,9,9a, 10-Q-octagidropyrimido (4.5-9 ) quinoling- - rochloride on the sexual behavior of female mammals has been evaluated in our ovaries of exrogated rats. The change in the ratio of the number of spinal curvatures per heel was measured. Table 9 presents the results of this experiment.
A similar experiment was conducted on two stereoisomers: trans - (-) - 2- -amin-6-p-propyl-5,5a, 6,7,8,9,9a, 10--oct-hydropyrimido (4,5-d) quinoline and trans - (+) - isomer. The response to the trans - (+) - isomer was slightly more than the response to the pure carrier (0.093 ± 0.063 to 0.035 ± 0.018), while the trans - (-) - isomer showed a highly significant change of 0.753 ± 0.031.
In tab. 10 shows the effect of the dose of trans - (-) - 2-amine-6-p-propyl-5,5a, 6, - 7,8,9,9a, 10-octahydropyrimido (4,5-j) - quinodine on the ratio the number of spinal curvatures per cage in exogenous-treated rats deprived of ovary. All values are X i CO for 19 animals (subcutaneously) and. for 8 animals when taken by mouth (water as a carrier).
136423
15
35
40
45
50
55
ten
20
25

Q -

423J 20
The response to carrier behavior was significantly lower (, 1) than the response to drug behavior at all doses and routes of administration.
trans - (+) - stereoisomers or 5aS, 9a5 stereoisomers are dopamine-d-1 agonists. They are D-1 agonist activity in several ways. One way is to stimulate the formation of cyclical. ACF in the rat's striatal membrane.
5aS, 9a8-2-Amin-6 P-propyl-5 "5a, - 15 10-octahydropyrimido (4,5- -) quinoline, 5aR, 9aC-enntiomer and correspondingly, the racemate is tested for their ability to activate .-clase in the membrane of the banded rat, measured as an increase in the concentration of cyclic AMP (adenosine-5-monofysfat). The results are given in Table. 11. Dopamine was used as a positive control.
In the presence of 10 μmol GTP, the main activity of adenylate cyclase in the membranes of the striatum of a rat has the value + S.O. values 196.2 + 20.3 pmol / min / mg protein. Compounds were studied three times.
In accordance with the table. 10, 5aS 9a3 enantiomer significantly increased the formation of cyclic AMP, and the significant activity of the D-1-dopamine agonist was determined. It was more active than the racemate, while the increase in cyclic AMP induced by the 4aR, 9aK enantiomer barely satisfied the required significance level.
A second, particularly sensitive indicator of the activity of a D-1 agonist is the determination of cyclic AMP efflux in thin tissue sections using the Stoof procedure. In this procedure, the striatum tissue is cut off from the rat brain and crumbled into fragments 0.3 x 0.3 mm. The tissue fragments are suspended in a suitable buffer system (e.g., Earl balanced salt solution), and the suspension is continuously aerated with a mixture in a ratio of 95: 5 while the temperature is maintained. Freshly prepared tissue fragments are transferred to fresh medium, to which bovine short albumin (2.5 mg / ml) and 3-isos are added.
40
45
50
55
butyl-1-methylxanthin (1 mmol) to block the cleavage of cyclic AMP. Tissue fragments are incubated in a buffer solution without drugs and then transferred to the same medium with the drugs added. Aliquots of the incubation medium, with and without drugs, are analyzed to determine the concentration of cyclic AMP by accurate radioimmunoassay. The effect of the drug on the expiration is expressed as a percentage of remaining and flowing.
The following medium was applied, mg / l:
6800 402.6
2201.1 137.99 147.88
1009 191.1
ten
The described experiments used sulpiride to suppress the negative (anti-0-1) effect of any drug acting as dopamine B-2 agonist. The authors have previously demonstrated that D-2 agonist suppresses the formation of cyclic AMP (the effect is opposite to that produced by 1-1 agonist). As is known, sulpiride is an antagonist of pituitary 1-2 receptors. Adding sulpiride to the studied
NaCl
KC1
NaHCOj
MgSO, -7H, 0
d-glucose
 2H, 0
Phenol red
AT
It blocks any 1-2 effects of the drug in restoring the production of cyclic AMP. The absence of the influence of sulpiride on the production of cyclic AMP in the striatum with the use of KF 38393 (1,2,3,4-tetrahydro-7,8-dioxy-1-phenyl-1H-3-benzazepine) as pure 1- 1-agonist indicating that 1-2 receptors were not affected and the compound did not show activity 1-2-agonist.
The results of one such determination for 5aS, 9a5-2-amine-6-p-propyl-5,5a, 6,7,8,9,9a, 10-octahydropyrimido- (4,5-d) quinoline dihydrochloride (compound A ) are given in Table. 12.
The acute toxicity of the proposed compounds was determined by oral administration of the Garln Fisher strain to rats.

15
ten

20
25
344. It has been established that the dose of half survival (LD. With a 95% guarantee limit) of the test compound when administered orally to rats is 197 (182-214) mg / kg (in terms of activity) for males and 234 (218 -252) mg / kg (in terms of. Activity for females.
Thus, the pyrimi-to-G4,5-d quinoline derivatives obtained by the proposed method fall into the category of medium toxic compounds, with the proposed compounds being active antagonists of D-1- and D-2--dopamine, which are not defective. any side effects that have, in addition, the ability to lower blood pressure and affect the sexual behavior of male mammals, which is a completely new property of pyrimido 4,5- (quinoline) compounds.

权利要求:
Claims (1)
[1]
Invention Formula
The method of producing pyrimido 4,5-quinoline derivatives of the general formula
.
thirty
-; cg
Cs
35
where R is C —C-alkyl-,
R2 - .NH, NHCHg, N (CE) R j - hydrogen,
RI
2
40
or their optically active isomers, or their pharmaceutically acceptable acid addition salts, characterized in that the compound of the general formula
0
XO
45
Where
K.
R has the specified value.
50
55
Y is acetyl or dimethylamine, or its optically active isomers are reacted with a compound of the general formula
  X NH, HN C
.
or its salt in an organic polar solvent at the boil and the desired product is isolated in free form or in the form of pharmaceutically acceptable acid addition salts.
t a b l and c a 1
Rzj
R,
5aR, 9aK isomer
Ri
Table3
Table4
Carrier (up to
Media (after processing)
37.5 (3/8)
Table3
Table
50.0 (7/14)
29
 Significantly more than the drug (P v 0.003)
Table9
Carrier
trans - (+) - racemate 25
trans - (-) - Stereoisomer25
 Significantly more than carrier, 05 Significantly more than trans - (+) - P 0.05.
Ay tables
Subcutaneously
The same - - Through the mouth
Also
1364238
thirty
Table
0.158 i 0.042 0.580 + 0.063
0.760 + 0.0580
+ -f
0.074 ± 0.025 0.284 + 0.064 0.405 ± 0.083 0.786 ± 0.028 0.008 ± 0.021 0.467 ± 0.033 0.558 + 0.063
31
71.6 ± 8.2
, 6
5 X 114.0 + 11.2
Editor M. Tsitkina
Compiled by V. Volkov Tehred L. Serdyukov
Order 6387/58 Circulation 372Subscription
VNIIPI USSR State Committee
for inventions and discoveries 113035, Moscow, Zh-35, Raushsk nab., 4/5
Production and printing company, Uzhgorod, st. Project, 4
1364238
32 Table 11
T a b e and c a 12
71.6 ± 8.2
14.0 + 11.2
About 60
Proofreader V. But ha

类似技术:

---

公开号 | 公开日 | 专利标题

---

SU1364238A3|1987-12-30|Method of obtaining derivatives of pyrimido /4,5-d/quinoline or their optically active isomers or their pharmaceutically acceptable additive salts of acid

---

KR930002492B1|1993-04-02|Process for preparation of 6-thioxanthine derivatives

---

PT100603A|1993-08-31|USE OF TRIPTAMINE ANALOGS, TRIPTAMINE ANALOGS, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM

---

HU180219B|1983-02-28|Process for producing substituted xantine derivatives and salts

---

JP2004315538A|2004-11-11|New 9-n-bicyclic nucleoside agent useful as selective inhibitor of proinflammatory cytokine

---

US20050026959A1|2005-02-03|Ethanol solvate of |-cis-2-|-5,7-dihydroxy-8-[4R-|piperidinyl]-4H-1benzopyran-4-one

---

Hardtmann et al.1975|Synthesis and biological evaluation of some 10-substituted 2, 3-dihydroimidazo [2, 1-b] quinazolin-5 |-ones, a new class of bronchodilators

---

US3966936A|1976-06-29|Piperazino quinazoline bronchodilators

---

KR870001159B1|1987-06-13|Process for preparing pyrazole-ring alkylated pyrazoloquinolines

---

EP0369145A2|1990-05-23|Pyrrolo[3,2-e]pyrazolo[1,5-a]pyrimidine derivatives and medicines comprising the same

---

US4528289A|1985-07-09|Corynantheine derivates, processes for their preparation, and their use

---

US4725687A|1988-02-16|5-methyl-5-deaza analogues of methotrexate and N10 -ethylaminopterin

---

DE1795022B2|1980-08-07|

---

RU2200737C2|2003-03-20|Pyrimido[4,5-b]indoles and intermediate compound |

---

EP0039913B1|1985-01-23|Tetrazolylcoumarin derivatives, process for preparing the same and composition containing the same

---

US6541482B2|2003-04-01|Carbocyclic nucleoside agents useful as selective inhibitors of proinflammatory cytokines

---

SU900807A3|1982-01-23|Process for producing carbazole derivatives

---

PL80112B1|1975-08-30|

---

US4455420A|1984-06-19|4-Amino-7-|-5-iodo-7H-pyrrolo[2,3-d] pyrimidine

---

IE59098B1|1994-01-12|Piperazinecarboxylic acid, its preparation and pharmaceutical compositions containing it

---

SU1421258A3|1988-08-30|Method of producing transoctahydrooxasol | quinoline or its pharmaceutically acceptable salts

---

EP0101162B1|1987-01-28|Novel 3-| ethyl)1,2,3,4-tetrahydro-5h|benzopyrano|pyridin-5-ones, pharmaceutical compositions containing them and processes for their production

---

FI57589B|1980-05-30|REFERENCE TO A FRAME TRACTOR 6-SUBSTITUTE 3-CARBETOXYHYDRAZINOPYRIDAZINER

---

DK169970B1|1995-04-18|Intermediates for use in the preparation of pyrimido [4,5-g] quinoline derivatives or salts thereof

---

FI85481C|1992-04-27|Process for preparing 2,3-dihydro-1- | -4 | -pyridinone

同族专利:

---

公开号 | 公开日

---

US4501890A|1985-02-26|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

US11242341B2|2016-10-06|2022-02-08|Assia Chemical Industries Ltd.|Solid state forms of valbenazine|US4198415A|1979-01-22|1980-04-15|Eli Lilly And Company|Prolactin inhibiting octahydro pyrazolo[3,4-g]quinolines|US4647667A|1982-11-03|1987-03-03|Eli Lilly And Company|Octa- and deca-hydroquinoline intermediates|

---

US4567266A|1982-11-03|1986-01-28|Eli Lilly And Company|Method of preparing octahydro-1H-pyrazolo[3,4-g]quinolines|

---

US4778894A|1983-09-26|1988-10-18|Eli Lilly And Company|6 oxo-decahydroquinolines|

---

US4599339A|1983-09-26|1986-07-08|Eli Lilly And Company|Use of pyrimido[4,5-g]quinolines in treating parkinsonism|

---

US4622398A|1985-06-24|1986-11-11|Eli Lilly And Company|Dialkylaminotetrahydroquinazoline|

---

US4831145A|1986-03-31|1989-05-16|Eli Lilly And Company|7-phenylsulfonyloxymethylene-6-oxo-perhydroquinolines|

---

US4764609A|1986-03-31|1988-08-16|Eli Lilly And Company|Synthesis of 2-aminopyrimido[4,5-g]quinolines|

---

US5134143A|1986-06-16|1992-07-28|Eli Lilly And Company|BCD tricyclic ergoline part-structure analogues|

---

US4977160A|1986-06-16|1990-12-11|Eli Lilly And Company|BCD tricyclic ergoline part-structure analogues|

---

US4826986A|1986-06-16|1989-05-02|Eli Lilly And Company|6-Oxo-trans-octa- and decahydroquinolines|

---

US4762843A|1986-09-15|1988-08-09|Warner-Lambert Company|Hetero [f] fused carbocyclic pyridines as dopaminergic agents|

---

US5196416A|1987-08-28|1993-03-23|Eli Lilly And Company|Transdermal flux-enhancing pharmaceutical compositions comprising azone, ethanol and water|

---

US5084480A|1987-11-06|1992-01-28|Fujisawa Usa, Inc.|Pentamidine salts useful in the treatment of pneumocystis carinii pneumonia|

---

US4977149A|1989-07-24|1990-12-11|Eli Lilly And Company|Pyridoquinoline dopamine agonists, compositions and use|

---

US4939259A|1989-07-24|1990-07-03|Eli Lilly And Company|2-oxo-pyrido[2,3-g]quinoline derivatives|

---

US5006525A|1989-07-24|1991-04-09|Eli Lilly And Company|Dopamine agonists method|

---

US5057515A|1989-07-24|1991-10-15|Eli Lilly And Company|Method for agonizing a dopamine receptor|

---

CA2095518A1|1990-11-14|1992-05-15|Jeffrey M. Blaney|Specific inhibition of dihydrofolate reductase and compounds therefor|

---

US5416090A|1991-01-31|1995-05-16|Eli Lilly And Company|Method of treating inflammation|

---

US5969136A|1992-10-15|1999-10-19|Eli Lilly And Company|Cyclization for preparing antifolate compounds|

---

US20030212085A1|2001-04-17|2003-11-13|Mccall Robert B.|Treatment of fibromyalgia and chronic fatigue syndrome|

---

DE10041478A1|2000-08-24|2002-03-14|Sanol Arznei Schwarz Gmbh|New pharmaceutical composition|

---

DE10334188B4|2003-07-26|2007-07-05|Schwarz Pharma Ag|Use of rotigotine to treat depression|

---

DE10334187A1|2003-07-26|2005-03-03|Schwarz Pharma Ag|Substituted 2-aminotetralins for the treatment of depression|

---

TWI537274B|2011-03-14|2016-06-11|橘生藥品工業股份有限公司|Novel octahydrothienoquinoline derivatives, pharmaceutical compositions containing the same, and their uses|

法律状态:

优先权:

---

申请号 | 申请日 | 专利标题

---

US06/535,503|US4501890A|1983-09-26|1983-09-26|Trans--2,4,6-substituted-5,5a,6,7,8,9,9a,10-octahydro-pyrimido[4,5-g]quinolines|

---